Uric Acid and Treatment With Empagliflozin in Heart Failure with Preserved Ejection Fraction (HFpEF): the EMPEROR-Preserved Trial

被引：0
|
作者：
Green, Jennifer [1 ,2 ]
机构：
[1] Duke Univ, Dept Med, Duke Clin Res Inst, Med Ctr, Durham, NC USA
[2] Duke Univ, Med Ctr, Div Endocrinol, Durham, NC USA
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2023年 / 142卷
关键词：
empagliflozin; heart failure; HFpEF; hyperuricemia; SGLT2;
D O I：
10.1016/j.metabol.2023.155468
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0074
引用
收藏
页码：S25 / S25
页数：1
相关论文
共 50 条
  • [21] Heart failure with a preserved ejection fraction and the EMPEROR-Preserved Trial: a review of how we got here
    de Abreu, Tiago Tribolet
    [J]. HEART FAILURE REVIEWS, 2022, 27 (06) : 2077 - 2082
  • [22] Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction A Post Hoc Analysis of the EMPEROR-Preserved Trial
    Butler, Javed
    Usman, Muhammad Shariq
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Boehm, Michael
    Brueckmann, Martina
    Januzzi, James L.
    Kaul, Sanjay
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Sumin, Mikhail
    Verma, Subodh
    Zaremba-Pechmann, Liliana
    Pocock, Stuart J.
    Packer, Milton
    Anker, Stefan
    [J]. JAMA CARDIOLOGY, 2023, 8 (07) : 640 - 649
  • [23] Effects of empagliflozin in patients with heart failure and preserved ejection fraction according to baseline diuretic use: results from the EMPEROR-Preserved trial
    Butler, J.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 : 982 - 982
  • [24] Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved
    Huynh, Karina
    [J]. NATURE REVIEWS CARDIOLOGY, 2021, 18 (11) : 737 - 737
  • [25] Outcomes of empagliflozin in patients with heart failure with a preserved ejection fraction and atrial fibrillation or atrial flutter: insights from EMPEROR-Preserved
    Filippatos, Gerasimos
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 134 - 135
  • [26] Empagliflozin improves clinical outcomes for HFpEF in EMPEROR-Preserved
    Karina Huynh
    [J]. Nature Reviews Cardiology, 2021, 18 : 737 - 737
  • [27] Empagliflozin and risk of lower respiratory tract infection in heart failure with mildly reduced and preserved ejection fraction: An EMPEROR-Preserved analysis
    Ferreira, Joao Pedro
    Zannad, Faiez
    Packer, Milton
    Filippatos, Gerasimos
    Pocock, Stuart J.
    Vasques-Novoa, Francisco
    Boehm, Michael
    Butler, Javed
    Anker, Stefan
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (04) : 952 - 959
  • [28] Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
    Pocock, Stuart J.
    Ferreira, Joao Pedro
    Packer, Milton
    Zannad, Faiez
    Filippatos, Gerasimos
    Kondo, Toru
    McMurray, John J., V
    Solomon, Scott D.
    Januzzi, James L.
    Iwata, Tomoko
    Salsali, Afshin
    Butler, Javed
    Anker, Stefan D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (10) : 1869 - 1878
  • [29] Letter by Gronda et al Regarding Article, "Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial"
    Gronda, Edoardo
    Colivicchi, Furio
    Zuccala, Giuseppe
    [J]. CIRCULATION, 2022, 145 (16) : E839 - E840
  • [30] Empagliflozin in the treatment of heart failure with preserved ejection fraction
    Morbach, C.
    Frantz, S.
    Nitschmann, S.
    [J]. INNERE MEDIZIN, 2022, 63 (07): : 808 - 809
12345